VEDOLIZUMAB: EARLY EXPERIENCE AND MEDIUM-TERM FOLLOW UP DATA FROM TWO UK TERTIARY IBD CENTRES - A RETROSPECTIVE COHORT STUDY



This item was part of UEG Week 2016